Publicaciones en colaboración con investigadores/as de Universidade de Santiago de Compostela (22)

2024

  1. Angiotensin type 1 receptor activation promotes neuronal and glial alpha-synuclein aggregation and transmission

    npj Parkinson's Disease, Vol. 10, Núm. 1

  2. Correction to: Pharmacological Modulators of Tau Aggregation and Spreading (Brain Sciences, (2020), 10, 11, (858), 10.3390/brainsci10110858)

    Brain Sciences

2022

  1. Endogenous Levels of Alpha-Synuclein Modulate Seeding and Aggregation in Cultured Cells

    Molecular Neurobiology, Vol. 59, Núm. 2, pp. 1273-1284

  2. Glycation modulates alpha-synuclein fibrillization kinetics: A sweet spot for inhibition

    Journal of Biological Chemistry, Vol. 298, Núm. 5

2021

  1. Doxycycline Interferes With Tau Aggregation and Reduces Its Neuronal Toxicity

    Frontiers in Aging Neuroscience, Vol. 13

  2. Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo

    Neurobiology of Disease, Vol. 151

2020

  1. Aging-Related Overactivity of the Angiotensin/AT1 Axis Decreases Sirtuin 3 Levels in the Substantia Nigra, Which Induces Vulnerability to Oxidative Stress and Neurodegeneration

    The journals of gerontology. Series A, Biological sciences and medical sciences, Vol. 75, Núm. 3, pp. 416-424

  2. Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization

    Scientific Reports, Vol. 10, Núm. 1

  3. Pharmacological modulators of tau aggregation and spreading

    Brain Sciences, Vol. 10, Núm. 11, pp. 1-29

  4. Synucleinopathies: Where we are and where we need to go

    Journal of Neurochemistry, Vol. 153, Núm. 4, pp. 433-454

2018

  1. Aging-related dysregulation in enteric dopamine and angiotensin system interactions: Implications for gastrointestinal dysfunction in the elderly

    Oncotarget, Vol. 9, Núm. 13, pp. 10834-10846

  2. Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson’s Disease Models

    Molecular Neurobiology, Vol. 55, Núm. 9, pp. 7297-7316

2017

  1. Dopamine modulates astroglial and microglial activity via glial renin-angiotensin system in cultures

    Brain, Behavior, and Immunity, Vol. 62, pp. 277-290

2015

  1. Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinsons Disease

    Neuroscientist, Vol. 21, Núm. 6, pp. 616-629

2014

  1. Aging-related dysregulation of dopamine and angiotensin receptor interaction

    Neurobiology of Aging, Vol. 35, Núm. 7, pp. 1726-1738

  2. Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β

    Experimental Neurology, Vol. 261, pp. 720-732

  3. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with l-DOPA

    Neuropharmacology, Vol. 76, Núm. PART A, pp. 156-168

2013

  1. Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells

    Experimental Neurology, Vol. 250, pp. 384-396

  2. Dopamine-Angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease

    Movement Disorders, Vol. 28, Núm. 10, pp. 1337-1342

  3. Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage

    Age, Vol. 35, Núm. 5, pp. 1675-1690